Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles
- 22 December 2021
- journal article
- research article
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 116 (7) , 438-454
Abstract
Developing new antibacterial drugs by using traditional ways is insufficient to meet existing challenges; hence, new strategies in the field of antibacterial discovery are necessary. An alternative strategy is to improve the efficacy of currently available antibiotics. Herein, the antibacterial efficacy of drugs (Cefixime, Sulfamethoxazole, and Moxifloxacin) and drug-loaded cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles (NPs) was elucidated versus Gram-negative bacteria (Pseudomonas aeruginosa, Klebsiella pneumoniae, neuropathogenic Escherichia coli K1 and Serratia marcescens) and Gram-positive bacteria (Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae, and Bacillus cereus). NPs were synthesized by co-precipitation and the Stöber method, and characterized by Fourier transform-infrared spectroscopy, Zetasizer, and Atomic force microscopy. Lactate dehydrogenase (LDH) assays were accomplished to determine drug cytotoxicity against human cells. Spherical NPs in the range of 118–362 nm were successfully synthesized. Antibacterial assays revealed that drugs conjugated with NPs portray enhanced bactericidal efficacies against multiple drug resistant bacteria compared to the drugs alone. Of note, Cefixime-conjugated NPs against Escherichia coli K1 and Methicillin- resistant Staphylococcus aureus, resulted in the complete eradication of all bacterial isolates tested at significantly lower concentrations compared to the antibiotics alone. Likewise, conjugation of Moxifloxacin resulted in the complete elimination of E. coli K1 and MRSA. Of note, nano-formulated drugs presented negligible cytotoxicity against human cells. These results depict potent, and enhanced efficacy of nano-formulated drugs against medically important bacteria and can be used as alternatives to current antibiotics. Future in vivo studies and clinical studies are warranted in prospective years to realize these expectations.Keywords
Funding Information
- the American University of Sharjah and University of Sharjah
- American University of Sharjah
This publication has 69 references indexed in Scilit:
- New antibiotic agents in the pipeline and how they can help overcome microbial resistanceVirulence, 2013
- The multifaceted roles of antibiotics and antibiotic resistance in natureFrontiers in Microbiology, 2013
- Serratia Marcescens - A Rare Opportunis - tic Nosocomial Pathogen and Measures to Limit its Spread in Hospitalized PatientsJournal of Clinical and Diagnostic Research, 2013
- Relationship of In Vitro Susceptibility to Moxifloxacin and In Vivo Clinical Outcome in Bacterial KeratitisClinical Infectious Diseases, 2012
- Lecithin-Based Novel Cationic Nanocarriers (Leciplex) II: Improving Therapeutic Efficacy of Quercetin on Oral AdministrationMolecular Pharmaceutics, 2011
- Increased osteoblast and decreased Staphylococcus epidermidis functions on nanophase ZnO and TiO2Journal of Biomedical Materials Research Part A, 2006
- MoxifloxacinDrugs, 2000
- Susceptibility of Escherichia coli with Capsular Antigen K1 Isolated from Urinary Tract Infection on the Joint Action of Cefotaxime and Normal Human SerumNephron, 1994
- CefiximeDrugs, 1989
- Infections Caused by Pseudomonas aeruginosaClinical Infectious Diseases, 1983